IMV (NYSE:IMV) has been given a $10.00 price objective by research analysts at Raymond James in a research report issued to clients and investors on Thursday, BayStreet.CA reports. The firm currently has an “outperform” rating on the stock. Raymond James’ target price points to a potential upside of 287.60% from the company’s current price.

IMV has been the subject of a number of other reports. Zacks Investment Research downgraded IMV from a “buy” rating to a “hold” rating in a report on Saturday, October 26th. HC Wainwright set a $11.50 price objective on IMV and gave the company a “buy” rating in a report on Monday, September 30th. Finally, Wells Fargo & Co assumed coverage on IMV in a report on Monday, October 28th. They issued a “market perform” rating for the company. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $8.94.

NYSE IMV traded down $0.30 on Thursday, reaching $2.58. The company had a trading volume of 8,241 shares, compared to its average volume of 19,864. IMV has a fifty-two week low of $2.25 and a fifty-two week high of $7.07. The business has a 50 day moving average of $2.74 and a two-hundred day moving average of $3.15.

IMV (NYSE:IMV) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.03). The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.05 million.

A number of institutional investors have recently modified their holdings of IMV. Morgan Stanley grew its holdings in IMV by 260.5% during the 2nd quarter. Morgan Stanley now owns 90,368 shares of the company’s stock worth $264,000 after acquiring an additional 65,300 shares during the period. Bank of Montreal Can grew its holdings in IMV by 17.5% during the 2nd quarter. Bank of Montreal Can now owns 88,889 shares of the company’s stock worth $260,000 after acquiring an additional 13,228 shares during the period. Citadel Advisors LLC acquired a new stake in IMV during the 2nd quarter worth about $37,000. Royal Bank of Canada grew its holdings in IMV by 3.6% during the 2nd quarter. Royal Bank of Canada now owns 98,676 shares of the company’s stock worth $288,000 after acquiring an additional 3,453 shares during the period. Finally, Hartford Financial Management Inc. grew its holdings in IMV by 9.6% during the 3rd quarter. Hartford Financial Management Inc. now owns 38,098 shares of the company’s stock worth $94,000 after acquiring an additional 3,348 shares during the period.

IMV Company Profile

IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.

Recommended Story: NASDAQ Stock Market Explained

Analyst Recommendations for IMV (NYSE:IMV)

Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with's FREE daily email newsletter.